Vaccine · Immune activation, directed at melanoma-associated tumor stem cell antigens · developed by Lisata Therapeutics
Eltrapuldencel-T is an autologous dendritic cell vaccine pulsed with antigens from lethally irradiated, patient-specific melanoma cells and suspended in GM-CSF. It is given subcutaneously to stimulate a cytotoxic T-lymphocyte response against melanoma-associated antigens, and is studied in stage III and stage IV melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01875653 | Phase 3 | Stage IV Melanoma | Terminated | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Stage III MelanomaStage IV Melanoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →